WO2018162785A3 - Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato - Google Patents

Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato Download PDF

Info

Publication number
WO2018162785A3
WO2018162785A3 PCT/ES2018/070184 ES2018070184W WO2018162785A3 WO 2018162785 A3 WO2018162785 A3 WO 2018162785A3 ES 2018070184 W ES2018070184 W ES 2018070184W WO 2018162785 A3 WO2018162785 A3 WO 2018162785A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
oxalate
compounds
diseases caused
patients
Prior art date
Application number
PCT/ES2018/070184
Other languages
English (en)
French (fr)
Other versions
WO2018162785A2 (es
Inventor
Mónica Díaz Gavilán
José Antonio GÓMEZ VIDAL
María Dolores Moya Garzón
Eduardo Salido Ruiz
Cristina Martín Higueras
Miguel Xavier Fernandes
Original Assignee
Universidad De Granada
Universidad De La Laguna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Granada, Universidad De La Laguna filed Critical Universidad De Granada
Priority to EP18764805.0A priority Critical patent/EP3593803A4/en
Priority to US16/492,750 priority patent/US20200197418A1/en
Publication of WO2018162785A2 publication Critical patent/WO2018162785A2/es
Publication of WO2018162785A3 publication Critical patent/WO2018162785A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal

Abstract

La presente invención se refiere al uso de derivados del ácido salicílico, para el tratamiento de enfermedades o patologías relacionadas la actividad de las enzimas GO y/o PRODH2, en particular en enfermedades relacionadas con un exceso de oxalato, y para el tratamiento de pacientes con insuficiencia renal (uremia o hiperazoemia) que reciben hemodiálisis o diálisis peritoneal, en particular pacientes tratados con ácido ascórbico (vitamina C), que se metaboliza a oxalato o de pacientes con fibromialgia y dolor vulvar.
PCT/ES2018/070184 2017-03-10 2018-03-12 Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato WO2018162785A2 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP18764805.0A EP3593803A4 (en) 2017-03-10 2018-03-12 COMPOUNDS FOR TREATING DISEASES CAUSED BY OXALATE ACCUMULATION
US16/492,750 US20200197418A1 (en) 2017-03-10 2018-03-12 Compounds for the treatment of diseases caused by oxalate accumulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201730326 2017-03-10
ES201730326A ES2639863B1 (es) 2017-03-10 2017-03-10 Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato

Publications (2)

Publication Number Publication Date
WO2018162785A2 WO2018162785A2 (es) 2018-09-13
WO2018162785A3 true WO2018162785A3 (es) 2018-11-08

Family

ID=60151157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2018/070184 WO2018162785A2 (es) 2017-03-10 2018-03-12 Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato

Country Status (4)

Country Link
US (1) US20200197418A1 (es)
EP (1) EP3593803A4 (es)
ES (1) ES2639863B1 (es)
WO (1) WO2018162785A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109293606B (zh) * 2018-11-20 2022-07-12 西华大学 2,5-双取代呋喃衍生物及其作为sirt蛋白抑制剂在药物制备中的用途
CN109748789A (zh) * 2018-12-26 2019-05-14 中国药科大学 水杨酸类化合物及其医药用途
CN110934867B (zh) * 2019-12-25 2022-10-21 南方医科大学 Hao1抑制剂在制备抑制肿瘤肺转移前微环境形成及防治肿瘤肺转移的药物中的应用
WO2022035805A1 (en) * 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558641A (en) * 1967-10-06 1971-01-26 Merck & Co Inc Certain pyridyl salicylic acid derivatives
JPH111464A (ja) * 1997-06-13 1999-01-06 Mitsui Chem Inc ジカルボン酸類化合物及びその製造方法
EP1802297B1 (en) * 2004-10-21 2011-03-30 The Burnham Institute Compositions and methods for treatment of disease caused by yersinia spp infection
CN101679244B (zh) * 2007-04-11 2014-01-01 橘生药品工业株式会社 5元杂环衍生物及其医药用途
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3344604B1 (en) * 2015-09-02 2020-11-04 Sunshine Lake Pharma Co., Ltd. Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CANDICE B SUMMITT ET AL.: "Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria", BIOCHEMICAL JOURNAL, vol. 466, no. 2, 1 March 2015 (2015-03-01), GB, pages 273 - 281, XP055548563, ISSN: 0264-6021 *
CRISTINA MARTIN-HIGUERAS ET AL.: "Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 24, no. 4, 1 April 2016 (2016-04-01), US, pages 719 - 725, XP055307346, ISSN: 1525-0016, Retrieved from the Internet <URL:https://doi.org/10.1038/mt.2015.224> *
FARGUE SONIA ET AL.: "Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell -based cytotoxicity assay", BIOCHIMICA ET BIOPHYSICA ACTA . MOLECULAR BASIS OF DISEASE, vol. 1862, no. 6, 6 February 2016 (2016-02-06), AMSTERDAM, NL, pages 1055 - 1062, XP055548550, ISSN: 0925-4439 *
FARGUE SONIA ET AL.: "Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1", BIOCHIMICA ET BIOPHYSICA ACTA OCT 2013, vol. 1832, no. 10, 30 September 2013 (2013-09-30), pages 1776 - 1783, XP055548543, ISSN: 0925-4439 *
KLESSIG DANIEL F ET AL.: "Multiple Targets of Salicylic Acid and Its Derivatives in Plants and Animals", FRONTIERS IN IMMUNOLOGY SWITZERLAND 2016, vol. 7, 26 May 2016 (2016-05-26), pages 206, XP055548590, Retrieved from the Internet <URL:doi:10.3389/fimmu.2016.00206> *
LORENZO VICTOR ET AL.: "Primary hyperoxaluria", NEFROLOGIA: PUBLICATION OFICIAL DE LA SOCIEDAD ESPANOLA NEFROLOGIA SPAIN, vol. 34, no. 3, 21 May 2014 (2014-05-21), pages 398 - 412, XP055548556, ISSN: 1989-2284, Retrieved from the Internet <URL:doi:10.3265/Nefrologia.pre2014.Jan.12335> *
STENBERG K A J ET AL.: "Three-dimensional structure of glycolate oxidase with bound active-site inhibitor", PROTEIN SCIENCE, vol. 6, 1 January 1997 (1997-01-01), US, pages 1009 - 1015, XP055548586, ISSN: 0961-8368 *

Also Published As

Publication number Publication date
EP3593803A2 (en) 2020-01-15
WO2018162785A2 (es) 2018-09-13
ES2639863A1 (es) 2017-10-30
EP3593803A4 (en) 2020-04-08
ES2639863B1 (es) 2018-09-20
US20200197418A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
WO2018162785A3 (es) Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato
EA201790658A1 (ru) Производные диарилмочевины в качестве ингибиторов киназы p38
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MA38399B2 (fr) Formulation sous forme de comprimé, utile pour traiter l&#39;insuffisance cardiaque aiguë et l&#39;insuffisance cardiaque chronique
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
PH12015500954A1 (en) Device for extracorporeal blood treatment
BR112013026319A2 (pt) método e aparelho para o monitoramento de um tratamento de um paciente, preferivelmente para o monitoramento da hemodiálise, hemodiafiltração e/ou diálise peritoneal
MX2019005300A (es) Polimeros enlazados al proton para administracion oral.
EP3310256A4 (en) Transcutaneous measurement of hemoglobin changes to calculate estimated blood volume change during peritoneal dialysis
MX2017013680A (es) Dispositivo de baño medico.
JO3649B1 (ar) بيبريدينيل تترا هيدرو كوينولينات مستبدلة
EA201600288A1 (ru) Замещенные фенилаланиновые производные
TN2016000249A1 (en) Substituted piperidinyl-tetrahydroquinolines.
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
WO2013155528A3 (en) Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels
EA201691055A1 (ru) Препараты и способы лечения gd2-положительного рака
BR112022003719A2 (pt) Métodos para o tratamento de hiperfenilalaninemia
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
UA86387U (ru) Способ оценки эффективности лечения больных с артериальной гипертензией, объединенной с метаболическим синдромом
MX2019005670A (es) Secuelas de lesion pulmonar inducida por baipas cardiopulmonar.
GR1008769B (el) Οξινο διαλυμα αιμοκαθαρσης με l-ασκορβικο οξυ (βιταμινη c)
EA201690788A1 (ru) Фармацевтические лекарственные формы, содержащие натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1h-1,2,3-триазол-1-ил)-1н-пиразол-5-олат
CY1124001T1 (el) Υγρο αιμοκαθαρσης απαλλαγμενο απο ασβεστιο
UA129572U (uk) Добавка дієтична для застосування при онкологічних захворюваннях
RU2012115039A (ru) Способ лечения хронического эндометрита

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018764805

Country of ref document: EP

Effective date: 20191010

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18764805

Country of ref document: EP

Kind code of ref document: A2